MENLO PARK, Calif., July 27, 2017 (GLOBE NEWSWIRE) -- CohBar, Inc. CWBR (TSX-V:COB.U), a preclinical stage biotechnology company focused on developing mitochondria based therapeutics (MBTs) to treat age-related diseases, announced today that the Company will release its second quarter 2017 financial results on Monday, August 14, 2017 and will host a conference call for the shareholders at 2:00 p.m. (Pacific Time) the same day.
Conference Call Information:
Date: August 14, 2017
Time: 2:00 p.m. (Pacific Time)
Dial-in U.S. and Canada: 1-888-245-0932
Dial-in International: 1-719-325-4835
Conference ID# 7589075
An audio recording of the call will be available beginning at 5:00 p.m. (Pacific Time) on August 14, 2017, through 9:00 p.m. (Pacific Time) on August 28, 2017. To access the recording please dial 1-844-512-2921 in the U.S. and Canada or 1-412-317-6671 internationally and reference Conference ID# 7589075.
About CohBar
CohBar CWBRCOB is a preclinical stage biotechnology company focused on the research and development of mitochondria based therapeutics (MBTs), an emerging class of drugs for the treatment of age-related diseases. MBTs originate from the discovery by CohBar's founders of a novel group of peptides within the mitochondrial genome which regulate metabolism and cell death, and whose biological activity declines with age. CohBar's efforts focus on the development of these mitochondrial-derived peptides (MDPs) into clinically relevant MBTs that offer the potential to address a broad range of age-related diseases, including obesity, fatty liver disease (NASH), type 2 diabetes, cancer, cardiovascular and neurodegenerative diseases. To date, the Company and its founders have discovered more than 65 biologically active MDPs.
For additional company information, please visit www.cohbar.com.
Investor and Media Contact: Jeff Biunno, CFO CohBar, Inc. (650) 446-7888 ext. 109 jeff.biunno@cohbar.com
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.